Durden ED, Bizier R, Huse D Thomson Medstat, Cambridge, MA, USA OBJECTIVES: The American Diabetes Association recommends treating diabetes patients to a target hemoglobin A1c level of 7% or less. Our objective was to examine the influence of A1c test results on decisions to initiate exogenous insulin supplementation in Type 2 diabetes. METHODS: A database of clinical laboratory results linked to health plan claims (MarketScan Lab) was used to identify patients with a diagnosis of Type 2 diabetes. Their first A1c test result between July 2003 and June 2005 was identified and patients were classified as at target (less than 7), above target (7-9), or poorly controlled (>9). The study sample was restricted to patients who had 6 months of claims history prior to and 6 months after the index test, and who received only oral antidiabetes therapy during the pre-test period. Addition of insulin to the regimen within 6 months after the test was assessed. RESULTS: A total of 4836 patients were identified, including 2450 (51%) who were at target, 1567 (32%) above target, and 819 (17%) poorly controlled. Insulin was added to the regimen of 12.9% of patients with poor control, 4.3% of those above target, and 1.5% of those at target (p < 0.00001). Among poorly controlled patients insulin was added in 22.0% of patients already on 3 oral medications, 12.6% of those with 2 oral medications, and 8.6% of those with 1 oral medication (p < 0.001). A1c test result and prior oral medication use remained significant predictors of insulin supplementation after controlling for demographic variation. CONCLUSION: High levels of A1c indicating poor glycemic control led some patients with Type 2 diabetes to initiate insulin supplementation, particularly those already receiving multiple oral medications. However, poorly controlled patients were still most likely to remain on oral therapy only, even if they were already using 3 or more medications.
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IMPACT OF PATIENT EDUCATION ON HBA1C REDUCTION IN DIABETIC PATIENTS WITH CONCOMITANT HYPERTENSION
Shaya FT 1 , Samant ND 1 , Saunders E 2 1 University of Maryland School of Pharmacy, Baltimore, MD, USA, 2 University of Maryland School of Medicine, Baltimore, MD, USA OBJECTIVES: The purpose of this study was to assess the impact of patient and physician education on Hemoglobin A1c (HbA1c) control in diabetes patients with concomitant hypertension. METHODS: The analysis was based on a subset of those enrolled in the Baltimore Partnership Programs to Reduce CVD Disparities project, with one year of follow-up. Patients and their physicians were randomly assigned to either intervention or control group, in a 2X2 nested case control factorial design. Patients and physicians participated in educational sessions. We calculated the change in HbA1c value, from baseline, to one year follow-up. Multiple regression was used to assess the effects of interventions on HbA1c change adjusting for age, race, gender and hypertension. RESULTS: Out of the study cohort of 114 patients, most were African American (96%) and female (62%). Mean baseline HbA1c values were higher among males vs. females (8.7% vs. 8.6%), African Americans vs. Caucasians (8.7% vs. 8.15%), Intervention patients vs. control patients (9.15% vs. 8.28%), and patients of Intervention vs. control physicians (8.94% vs.8.33%). The drop in the HbA1c values was greater among intervention patients (−0.6 vs. 0.2) and patients of intervention physicians (−0.32 vs. 0.01). After controlling for age, race, gender and hypertension, the drop in HbA1c in the patient intervention group was greater than the control and the drop in HbA1c in the patients of intervention physicians was greater than the control though statistically nonsignificant. CONCLUSION: In this patient sample, greater drop in HbA1c is seen among the intervention patients and patients of Intervention physicians. These results highlight the influence of patient and physician interventions supporting Diabetes disease management programs.
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PDB24 PRELIMINARY VALIDATION OF THE COGNITIVE DISTRESS, FATIGUE, HYPERGLYCEMIA AND HYPOGLYCEMIA SUBSCALES OF THE DIABETES SYMPTOM CHECKLIST REVISED (DCSR) FOR USE IN CLINICAL TRIALS INVOLVING PATIENTS WITH TYPE 1 OR TYPE 2 DIABETES
Kelly AA 1 , Hayes RP 2 1 Florida A&M University, Tallahassee, FL, USA, 2 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: The Diabetes Symptom Checklist-Revised (DSCR) is a 34-item, 7-subscale instrument designed to provide a comprehensive measure of diabetes-associated symptoms. When evaluating antihyperglycemic medications in a clinical trial however, only those symptoms affected by fluctuations in glycemic control (e.g., hyperglycemia) would be expected to change. Therefore, the objective of this study was to validate the DSC-R Cognitive Distress, Fatigue, Hyperglycemia, and Hypoglycemia subscales as individual measures of symptom groups to be targeted in clinical trials of antihyperglycemic medications. METHODS: In two clinical trials evaluating antihyperglycemic medications (Study 1: insulin therapy in 137 patients with type 1 diabetes; Study 2: oral therapy in 150 patients with type 2 diabetes), participants were administered the DSC-R at several time periods including screening, baseline and endpoint. To confirm the factorial validity of the subscales, a promax factor analysis
